The oral selective sphingosine-1-phosphate (S1P) receptor modulator ozanimod induced significant improvements in clinical remission and response, which were sustained up to 52 weeks, in patients with moderate-to-severe ulcerative colitis (UC), according to the phase III True North study presented at AIBD 2020 Congress.
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.
Removal of the gallbladder (ie, cholecystectomy) is not recommended at the time of intestinal resection among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2020.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.